Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Travere Therapeutics, Inc.

https://travere.com/

Latest From Travere Therapeutics, Inc.

Alnylam/Regeneron Face Crowded IgA Nephropathy Field, But Combinations Likely

Phase II data position cemdisiran well for Phase III, but several agents are already well ahead. However, Alnylam foresees a polypharmacy approach.

Renal Business Strategies

Deal Watch: Ovid Teams With Gensaic On Phage-Derived, Gene-Delivered Therapies

Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.

Deal Watch Business Strategies

COVID-19 Vaccine Skycovion Among Raft Of New EU Filings

EU marketing authorization applications for 12 products, including Skycovion, trastuzumab duocarmazine, alpelisib and sparsenta, are now being evaluated by the European Medicines Agency.

Drug Review Approvals

Roche To Take Ionis Drug Forward Into Crowded Nephropathy Field

Roche is not disclosing Phase II results yet, but must exceed late-stage rival drug’s 50% reduction in protein build up to compete in immunoglobulin A nephropathy.

Deals Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Desert Gateway, Inc.
    • Kyalin Biosciences, Inc.
    • Manchester Pharmaceuticals LLC.
    • Orphan Technologies Ltd.
    • Retrophin, Inc.
UsernamePublicRestriction

Register